Pharmafile Logo
Pharmafocus logo
Advanced Search

Revlimid

Showing 12 posts of 27 posts found.

revlimid_celgene

Celgene threatens to scale back UK clinical trial investment after CDF snub

September 4, 2015
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs

One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …

News

FDA in Novartis cancer drug U-turn

February 24, 2015
Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma

The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …

News
Revlimid image

Celgene gets FDA licence extension for myeloma drug

February 19, 2015
Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma

The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …

News
Sam Pierce image

Celgene UK: market access is a complex business

December 15, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce

Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …

Feature
celgene_1_02_1

NICE won’t back Revlimid in new setting

July 31, 2014
Medical Communications, Sales and Marketing Celgene, NICE, Revlimid, Thalidomide, multiple myeloma

NICE has once again said it does not think that Celgene’s rare cancer drug Revlimid should be used on the …

News
celgene_1_02_4

Celgene ‘stops Mylan entering market’

April 6, 2014
Sales and Marketing Celgene, Mylan, Revlimid, myeloma

Generic manufacturer Mylan is suing Celgene in a spat over allowing copycat versions of existing cancer drugs – Revlimid and …

News
Celgene image

Celgene ‘downplayed’ Thalomid, Revlimid risks

February 7, 2014
Medical Communications, Sales and Marketing Celgene, Revlimid, Thalidomide, thalomid

A former sales representative for US pharma firm Celgene is accusing her old company of promoting two of its key …

News
janssen image

Janssen/Pharmacyclics gain FDA nod for Imbruvica

November 14, 2013
Sales and Marketing FDA, Janssen, Pharmacyclics, Revlimid, Velcade

The FDA has approved Janssen and Pharmacyclics’ Imbruvica to treat patients with mantle cell lymphoma (MCL), a rare and aggressive …

News
Celgene image

NICE no for Celgene’s Revlimid

July 11, 2013
Sales and Marketing Celgene, NICE, Revlimid

NICE has issued new draft guidance not recommending Celgene’s bone marrow disorder drug Revlimid over uncertainties of its efficacy. Revlimid …

News
Celgene image

Revlimid patient scheme ‘working’

December 14, 2012
Sales and Marketing Celgene, Revlimid

Celgene has issued figures which it says demonstrate the clinical value of the NICE-agreed patient access scheme for its cancer …

News

Celgene

January 1, 2010
Research and Development, Sales and Marketing Abraxane, Celgene, Revlimid, Thalidomide

Founded in 1986, Celgene was created as a spin off from the Celanese Corporation. Two years later, the company received …

Feature

Patient wins legal battle for Revlimid

September 12, 2008
Sales and Marketing Cancer, Revlimid

A cancer patient has won access to cancer drug Revlimid in a court battle with his local PCT. West Sussex …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025